It is likely that the dysregulated expression of TIF1γ in the tumor microenvironment may contribute to the loss of immune tolerance and the formation of cross-reactive autoantibodies with the subsequent development of DM [11]. The gene discussed is TRIM33; the disease is diabetes mellitus.